Brain Norepinephrine: Neurobiology and Therapeutics

Drugs that manipulate central nervous system (CNS) norepinephrine have been used therapeutically for over 50 years. Even today, drugs are being developed that target noradrenergic neurons to deliver therapeutic effects, and new disease indications are being identified for existing and newer noradrenergic drugs. Recent discoveries about norepinephrine’s contribution to health, disease, and therapy make this synthesis of evidence, practice, and research very timely. A team of experts provides the reader with a thorough understanding of the anatomy, physiology, molecular biology, pharmacology, and therapeutics of norepinephrine in the brain, including an extensive review of the role of norepinephrine in brain diseases. The book is divided into four sections: the basic biology of norepinephrine; the role that norepinephrine plays in behavior; evidence of pathology of norepinephrine in CNS diseases, and the pharmacology and therapeutics of noradrenergic drugs in the treatment of psychiatric and neurological disorders.

Gregory A. Ordway is Chair of the Department of Pharmacology at the James H. Quillen College of Medicine at East Tennessee State University.

Michael A. Schwartz is Clinical Professor of Psychiatry at the University of Hawai‘i at Manoa.

Alan Frazer is Chair of the Department of Pharmacology at the University of Texas Health Sciences Center at San Antonio.
Brain Norepinephrine

Neurobiology and Therapeutics

Edited by

Gregory A. Ordway, Ph.D.
Department of Pharmacology, East Tennessee State University

Michael A. Schwartz, M.D.
Department of Psychiatry, University of Hawai‘i at Manoa

Alan Frazer, Ph.D.
Department of Pharmacology, University of Texas Health Science Center, San Antonio
Contents

List of contributors viii
Acknowledgements xii

Introduction: revision of an old transmitter 1
Gregory A. Ordway, Ph.D.

Part I The neurobiology of norepinephrine

1 Neuroanatomical and chemical organization of the locus coeruleus 9
   Kimberly L. Simpson, Ph.D. and Rick C. S. Lin, Ph.D.

2 Interactions of norepinephrine with other neurotransmitter systems: anatomical basis and pharmacology 53
   Craig A. Stockmeier, Ph.D. and Gregory A. Ordway, Ph.D.

3 Receptors for norepinephrine and signal transduction pathways 68
   David B. Bylund, Ph.D.

4 Regulation of gene transcription in the central nervous system by norepinephrine 95
   Ronald S. Duman, Ph.D. and Samuel S. Newton, Ph.D.

5 The norepinephrine transporter and regulation of synaptic transmission 119
   Subbu Apparsundaram, Ph.D.

Part II Norepinephrine and behavior

6 Role of the locus coeruleus-norepinephrine system in arousal and circadian regulation of the sleep–wake cycle 157
   Gary S. Aston-Jones, Ph.D., Monica Gonzalez, and Scott Doran
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Author(s)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>The locus coeruleus and regulation of behavioral flexibility and</td>
<td>Gary S. Aston-Jones, Ph.D., Michiyo Iba, Edwin</td>
<td>196</td>
</tr>
<tr>
<td></td>
<td>attention: clinical implications</td>
<td>Clayton, Janusz Rajkowski, and Jonathan Cohen</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Norepinephrine and long-term memory function</td>
<td>Benno Roozendaal Ph.D.</td>
<td>236</td>
</tr>
<tr>
<td>9</td>
<td>Norepinephrine and stress</td>
<td>David A. Morilak, Ph.D.</td>
<td>275</td>
</tr>
<tr>
<td>10</td>
<td>Animal models of psychopathology: focus on norepinephrine</td>
<td>Leonie A. M. Welberg, Ph.D. and Paul M. Plotsky, Ph.D.</td>
<td>299</td>
</tr>
<tr>
<td>11</td>
<td>Neuropathology of central norepinephrine in psychiatric disorders:</td>
<td>Gregory A. Ordway, Ph.D.</td>
<td>341</td>
</tr>
<tr>
<td></td>
<td>postmortem research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Norepinephrine in mood disorders</td>
<td>Pedro L. Delgado, M.D. and Cristinel Coconcea, M.D.</td>
<td>363</td>
</tr>
<tr>
<td>13</td>
<td>Noradrenergic pathology and pain</td>
<td>Antti Pertovaara, M.D., Ph.D.</td>
<td>385</td>
</tr>
<tr>
<td>14</td>
<td>Norepinephrine and cognitive disorders</td>
<td>Amy F. T. Arnsten, Ph.D.</td>
<td>408</td>
</tr>
<tr>
<td>15</td>
<td>Norepinephrine in neurological disorders</td>
<td>Francesco Formai, M.D., Ph.D.</td>
<td>436</td>
</tr>
<tr>
<td>16</td>
<td>Genetics of noradrenergic neurobiology</td>
<td>Inna Belfer, M.D., Ph.D. and David Goldman, M.D.</td>
<td>472</td>
</tr>
<tr>
<td>17</td>
<td>Actions of antidepressant and other drugs on norepinephrine systems</td>
<td>Elliott Richelson, M.D.</td>
<td>515</td>
</tr>
<tr>
<td>18</td>
<td>The clinical role of norepinephrine antidepressants in depression</td>
<td>J. Craig Nelson, M.D.</td>
<td>535</td>
</tr>
<tr>
<td></td>
<td>and anxiety disorders</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Part III  The biology of norepinephrine in CNS pathology

Part IV  Psychopharmacology of norepinephrine
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Norepinephrine in attention-deficit/hyperactivity disorder</td>
<td>557</td>
</tr>
<tr>
<td></td>
<td>Fred W. Riemherr, M.D., Michael A. Schwartz, M.D., B. K. Marchant,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and E. Higgins, M.D.</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Psychopharmacology of norepinephrine in eating disorders</td>
<td>595</td>
</tr>
<tr>
<td></td>
<td>Katherine A. Halmi, M.D. and Sun Young Yum</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Role of norepinephrine in substance abuse</td>
<td>610</td>
</tr>
<tr>
<td></td>
<td>Susan L. Broom, Ph.D. and Bryan K. Yamamoto, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

Index 628
Contributors

Subramaniam Apparsundaram, Ph.D.
Department of Anatomy and Neurobiology
University of Kentucky Chandler Medical Center
Rm MN 225
Lexington KY 40536
USA

Amy F. T. Arnsten, Ph.D.
Yale University School of Medicine
Section of Neurobiology
333 Cedar Street
New Haven, CT 06510
USA

Gary S. Aston-Jones, Ph.D.
Department of Psychiatry
University of Pennsylvania
VAMC, Bldg. 21, Room 520, Mail Code 151
University Woodland Aves
Philadelphia, PA 19104
USA

Inna Belfer, M.D., Ph.D.
Pain and Neurosensory Mechanisms Branch
National Institute of Dental and Craniofacial Research
Bethesda
USA

Susan L. Broom, Ph.D.
Department of Pharmacology
Boston University School of Medicine
Room L-613
80 E. Concord Street
Boston, MA 02118
USA

David B. Bylund, Ph.D.
Department of Pharmacology
University of Nebraska Medical Center
986260 Nebraska Medical Center
Omaha, NE 68198-6260
USA

Edwin Clayton
Department of Psychiatry
University of Pennsylvania
VAMC, Bldg. 21, Room 520, Mail Code 151
University Woodland Aves
Philadelphia, PA 19104
USA

Cristinel Coconcea, M.D.
Department of Psychiatry
University Hospital of Cleveland and Case Western Reserve University School of Medicine
Hanna Pavilion
11110 Euclid Avenue
Cleveland OH 44106-5000
USA

Jonathan Cohen
Department of Psychology
Princeton University
Pedro L. Delgado, M.D
Chair, Department of Psychiatry
University of Texas Health Science Center
Dept Psychiatry
7703 Floyd Curl Drive
San Antonio TX 78229-3900
USA

Scott Doran
Department of Psychiatry
University of Pennsylvania
VAMC, Bldg. 21, Room 520, Mail Code 151
University Woodland Aves
Philadelphia, PA 19104
USA

Ronald S. Duman, Ph.D.
Department of Psychiatry
Yale University School of Medicine
34 Park Street
New Haven, CT 06508
USA

Francesco E. Fornai, M.D., Ph.D.
University of Pisa
Department of Human Morphology and
Applied Biology
Via ROMA 55
Pisa 55100
Italy

Alan Frazer, Ph.D.
Professor and Chairman
Department of Pharmacology
University of Texas Health Science Center
San Antonio
7703 Floyd Curl Drive MSC 7764
San Antonio, TX 78229-3900
USA

David Goldman, M.D.
12420 Parklawn Drive
Suite 451, MSC 8110
Rockville, MD 20852
USA

Monica Gonzalez
Department of Psychiatry
University of Pennsylvania
VAMC, Bldg. 21, Room 520, Mail Code 151
University Woodland Aves
Philadelphia, PA 19104
USA

Katherine A. Halmi, M.D.
Professor of Psychiatry
Weill Medical College of Cornell University
21 Bloomingdale Road
White Plains, NY 10605
USA

E. Higgins, M.D.
Medical University of South Carolina
USA

Michiyo Iba
Department of Psychiatry
University of Pennsylvania
VAMC, Bldg. 21, Room 520, Mail Code 151
University Woodland Aves
Philadelphia, PA 19104
USA

Rick C. S. Lin, Ph.D.
Department of Anatomy
University of Mississippi Medical Center
2500 North State Street
Jackson, MS 39216
USA

B. K. Marchant
University of Utah
USA
List of contributors

David A. Morilak, Ph.D.
Department of Pharmacology
University of Texas Health Science Center
7703 Floyd Curl Drive
San Antonio, TX 78229-3900
USA

J. Craig Nelson, M.D.
Professor of Psychiatry
Director, Geriatric Psychiatry
University of California San Francisco
401 Parnassus Ave, PO Box 0984-F
San Francisco, CA 94143
USA

Samuel S. Newton, Ph.D.
Department of Psychiatry
Yale University School of Medicine
34 Park Stree
New Haven, CT 06508
USA

Gregory A. Ordway, Ph.D.
Professor and Chairman
Department of Pharmacology
James H. Quillen College of Medicine
East Tennessee State University
P.O. Box 70577
Johnson City, TN 37614
USA

Antti Pertovaara, M.D., Ph.D.
Department of Physiology
Institute of Biomedicine
University of Turku
Turku
Finland

Paul M. Plotsky, Ph.D.
Department of Psychiatry; Behavioral Science
Emory University School of Medicine
1639 Pierce Dr, WMRB 4105
Atlanta, GA 30322
USA

Janusz Rajkowski
Department of Psychiatry
University of Pennsylvania
VAMC, Bldg. 21, Room 520, Mail Code 151
University Woodland Aves
Philadelphia, PA 19104
USA

Fred W. Reimherr, M.D.
University of Utah
USA

Elliott Richelson, M.D.
Mayo Clinic of Jacksonville
4500 San Pablo Road
Jacksonville, FL 32224
USA

Benno Roozendaal, Ph.D.
Center for the Neurobiology of Learning and Memory
Bonney Research Laboratories, Rm #218
University of California,
Irvine, CA 92697-3800
USA

Michael Alan Schwartz, M.D.
Clinical Professor of Psychiatry
University of Hawai‘i at Manoa
1106 Blackacre Trail
Austin, Texas 78746
USA

Kimberly L. Simpson, Ph.D.
Department of Anatomy
University of Mississippi Medical Center
2500 North State Street
Jackson, MS 39216
USA
List of contributors

Craig A. Stockmeier, Ph.D.
Department of Psychiatry G127
University of Mississippi Medical Center
2500 North State Street
Jackson, MS 39216-4505
USA

Leonie M. Welberg, Ph.D.
Department of Psychiatry; Behavioral Science
Emory University School of Medicine
1639 Pierce Drive, WMRB 4105
Atlanta, GA 30322
USA

Bryan K. Yamamoto, Ph.D.
Department of Pharmacology
Boston University School of Medicine
Room L-613
80 E. Concord Street
Boston, MA 02118
USA

Sun Young Yum
Weill Medical College of Cornell University
21 Bloomingdale Road
White Plains, NY 10605
USA
Acknowledgements and Disclosures

Authors of this book were asked to disclose affiliations of financial involvement with any organization or entity having a financial interest in or financial conflict with the subject matter or materials discussed in their chapters. For purposes of disclosure, financial involvement is defined as having occurred in the last 3 years and being an amount greater than or equal to $10,000 per year, or having the potential to generate that amount per year in the future. The editors of the book have also disclosed any relevant affiliations or financial involvements.

Amy Arnsten and Yale University have license agreements with Shire Pharmaceuticals for the development of guanfacine, and with Marinus Pharmaceuticals for the development of chelerythrine for the treatment of prefrontal cortical disorders. These companies have also supported research in the Arnsten lab aimed at understanding the mechanism of action of these compounds.

Pedro Delgado has had funding for his research from The National Institutes of Health (R01 MH 48977 and R01 MH54648). He has had a financial interest or other relationships with the manufacturers of some commercial products as specified below:

Eli Lilly & Co  
GlaxoSmithKline  
Organon, Inc  
Wyeth-Ayerst  
Forest Laboratories  
Pierre Fabre  
Bristol Meyers Squibb  
Paramount Biosciences  
Concept Therapeutics  
Pfizer Inc  

Grant Support/Advisory Board/Speakers bureau  
Grant Support/Advisory Board/Speakers bureau  
Grant Support/Advisory Board/Speakers bureau  
Advisory Board/Speakers bureau  
Grant Support/Advisory Board  
Honorarium  
Advisory Board  
Consultant  
Grant Support  
Stock
### Acknowledgements and Disclosures

**Alan Frazer** has had a financial interest or other relationship with the manufacturers of some commercial products as specified below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyberonics Inc</td>
<td>Speakers bureau/Mechanism of Action Advisory Board Recipient of research grant</td>
</tr>
<tr>
<td>Forest labs/Lundbeck</td>
<td>Advisory Board member/Recipient of research grant</td>
</tr>
<tr>
<td>Lilly Labs</td>
<td>Consultant/Recipient of research grant</td>
</tr>
<tr>
<td>Servier</td>
<td>Recipient of research grant</td>
</tr>
<tr>
<td>Wyeth Labs</td>
<td>Consultant</td>
</tr>
</tbody>
</table>

**Edward S. Higgins** has been a consultant and member of the speakers bureau for Wyeth.

**Craig Nelson** has had a financial interest or other relationship with the manufacturers of some commercial products as specified below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott, Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Forest, GlaxoSmith Kline, Janssen, Pfizer, Wyeth</td>
<td>Lecture honoraria</td>
</tr>
<tr>
<td>Abbott, Biovail, Bristol Myers Squibb Corcept, Eli Lilly, GlaxoSmithkline, Orexigen, Organon, Pfizer, Sepracor, Shire</td>
<td>Consultation/Advisory Board</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>Research support</td>
</tr>
</tbody>
</table>

**Gregory A. Ordway** has funding for his research from The National Institutes of Health (MH46692, MH63187, MH02031, RR17701) and from Aventis.

**Antti Pertovaara** has had the following involvement with OrionPharma Inc, Helsinki, Finland: Inventor in one received US patent (no 5 541 211) and one pending US patent (no 2000 2011 5704), both of which are owned by OrionPharma Inc. Additionally, he is an inventor of one European patent (EP1198477) the owner of which is JuvantiaPharma Inc, Turku, Finland. He owns OrionPharma stocks worth USD 16,000. OrionPharma is an industrial partner in a research grant which he received from the Academy of Finland (grant no 105709; USD 180,000 for the period of 2004–2007).

**Paul M. Plotsky** has had a financial interest or other relationship with the manufacturers of some commercial products as specified below:

<table>
<thead>
<tr>
<th>Company</th>
<th>Relationship</th>
</tr>
</thead>
</table>
Acknowledgements and Disclosures


Fred W. Reimherr has had a financial interest or other relationship with the manufacturers of some commercial products as specified below:

Eli Lilly Consultant and multiple research grants Contracts through the University of Utah
Shire Consultant and independent research grant
McNeil (Johnson & Johnson) Consultant, speaker fees and independent research grant
Celgene Significant stock ownership

Elliott Richelson has had a financial interest or other relationship with the manufacturers of some commercial products as specified below:

Eli Lilly Advisory board for depression
Pfizer Inc Grant funding and Speaker bureau
Janssen Pharmaceuticals Grant funding

Michael A. Schwartz has had a financial interest or other relationship with the manufacturers of some commercial products as specified below:

Abbott Grant Support
Astra Zeneca Grant Support/ Speakers bureau
Bristol Meyers Squibb Grant Support/ Speakers bureau
Cephalon Speakers bureau
Eli Lilly Grant Support/ Advisory Board/ Speakers bureau
GlaxoSmithKline Grant Support/ Speakers bureau
Janssen Grant Support
King Speakers bureau
Shire Speakers bureau
Takeda Speakers bureau
Wyeth Grant Support/ Speakers bureau

The following authors had no relevant financial interests to disclose.

Subbu Apparsundaram
Gary S. Aston-Jones
Inna Belfer
Susan L. Broom
David B. Bylund
Edwin Clayton
Acknowledgements and Disclosures

Cristinel Coconeac
Jonathan Cohen
Ronald S. Duman
Katherine A. Halmi
Francesco Fornai
Monica Gonzalez
David Goldman
Michiyo Iba
C. S. Lin
Barrie K. Marchant
Samuel S. Newton
Janusz Rajkowski
Benno Roozendaal
David A. Morilak
Kimberly L. Simpson
Craig A. Stockmeier
Leonie A. M. Welberg
Bryan K. Yamamoto
Sun Young Yum

Scott Doran did not provide disclosures.